On July 17, 2025 Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) reported an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target (Press release, Ajax Therapeutics, JUL 17, 2025, View Source [SID1234654434]). The partnership was established in 2019 with a goal of leveraging Schrödinger’s advanced computational platform and Ajax’s structural biology insights to develop a pipeline of novel molecules, with a focus on JAK inhibitors. Ajax’s lead candidate from the collaboration, AJ1-11095, is a potential first-in-class Type II JAK2 inhibitor currently being evaluated in a Phase 1 clinical study for the treatment of myelofibrosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re excited to expand our longstanding research collaboration with Schrödinger," stated Martin Vogelbaum, chief executive officer of Ajax Therapeutics. "Given our teams’ history of success in creating more selective and potent JAK2 inhibitors, we expect to take a similar approach to this new JAK target with the goal of generating a new class of inhibitors that extend beyond oncology indications to include inflammatory and autoimmune disorders."

"Our collaboration with Ajax and the progress of AJ1-11095 demonstrates the power of combining our world-leading computational platform at scale with Ajax’s novel structural biology insights," stated Ramy Farid, Ph.D., chief executive officer of Schrödinger. "We are really pleased with the progress our teams have made over the course of this partnership, and we look forward to working with the Ajax team on this new JAK family target."

Abnormal JAK signaling is a key driver in myeloproliferative neoplasms, including myelofibrosis, as well as in inflammatory and autoimmune diseases. In collaboration with Schrödinger, Ajax is leveraging advanced computational methods and structural biology insights to develop next-generation inhibitors with the potential for greater selectivity and deeper, more durable responses compared to existing JAK inhibitors.

Under the terms of the amended agreement, Ajax and Schrödinger will collaborate on the discovery of the development candidate, and Ajax will be responsible for clinical development and commercialization. Schrödinger is eligible to receive discovery and development milestones similar to the terms of the original agreement. Schrödinger is also eligible to receive sales milestones and single-digit royalties on net sales of any products emerging from the additional target.

In 2024, Ajax completed an oversubscribed $95 million Series C financing, in which Schrödinger participated as a continuing investor. Schrödinger was a co-founder of Ajax and maintains an equity stake in the company.

About AJ1-11095

AJ1-11095 was designed using structure-based drug design and computational methods at scale to selectively bind the Type II conformation of the JAK2 kinase to provide greater efficacy with disease modification compared to all currently approved JAK2 inhibitors, including ruxolitinib, which bind the Type I conformation of JAK2. AJ1-11095 has been shown in preclinical studies to reverse marrow fibrosis, reduce mutant allele burden, and maintain efficacy against MPN cells that become resistant to chronic Type I JAK2 inhibition. AJ1-11095 is currently in a Phase I study for patients with MF who have been failed by a Type1 JAK2 inhibitor. Further details about the study can be found at www.clinicaltrials.gov.

On July 17, 2025 Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, reported that the Co-PSMA (NCT06907641)1 Investigator-Initiated Trial (IIT) led by Prof Louise Emmett at St Vincent’s Hospital Sydney has now completed study enrolment, with all participants having been imaged (Press release, Clarity Pharmaceuticals, JUL 17, 2025, View Source [SID1234654402]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study is evaluating the performance of Clarity’s diagnostic product, 64Cu-SAR-bisPSMA, in comparison to standard-of-care (SOC) 68Ga-PSMA-11 for the detection of prostate cancer recurrence in patients with low prostate-specific antigen (PSA) who are candidates for curative salvage therapy.

Co-PSMA (Comparative performance of 64Copper [64Cu]-SAR-bisPSMA vs. 68Ga-PSMA-11 PET CT for the detection of prostate cancer recurrence in the setting of biochemical failure following radical prostatectomy) is a prospective, Phase II imaging trial in 50 patients in biochemical recurrence (BCR) of prostate cancer. Eligible patients were required to have had radical prostatectomy with no salvage therapy and a PSA between 0.2 and 0.75 ng/mL. The primary objective of the trial is to compare the detection rate of sites of prostate cancer recurrence, as determined by number of lesions per patient, between 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT.

The diagnostic capabilities of 64Cu-SAR-bisPSMA compared to SOC diagnostic imaging have been demonstrated in two prospective clinical trials, PROPELLER2 and COBRA3. Following the positive results of these trials, Clarity is conducting two Phase III registrational trials, CLARIFY4 and AMPLIFY5, in the pre-prostatectomy and BCR settings, respectively. The CLARIFY trial is recruiting patients at St Vincent’s Hospital Sydney and this site will also open recruitment for the AMPLIFY trial shortly with Prof Emmett as the principal investigator.

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented, "We are excited about this important milestone in the Co-PSMA trial and the development program of 64Cu-SAR-bisPSMA. With mounting data of the benefits that 64Cu-SAR-bisPSMA could offer compared to SOC diagnostic imaging, demonstrated in the PROPELLER and COBRA trials, we eagerly anticipate the results from this head-to-head trial against 68Ga-PSMA-11.

"The high volume of patients imaged in recent months at a single site reflects the high unmet need for more effective diagnostic tools for men with rising PSA following radical prostatectomy. Visualising cancer early in these patients is crucial for physicians to determine the optimal course of treatment before the cancer spreads, leading to improved outcomes, including the potential for cure. We are very pleased to be able to support Prof Emmett, a world-renowned thought leader in the theranostics space, through the Co-PSMA trial in our own city of Sydney. We are honoured to continue working together on our pipeline of Targeted Copper Theranostics (TCTs) at St Vincents Hospital Sydney, as it is already actively recruiting patients for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial shortly."

Prof Louise Emmett (St Vincent’s Hospital Sydney), Principal Investigator in the Co-PSMA trial, commented, "We are pleased to have reached our enrolment target for the Co-PSMA trial. Imaging prostate cancer patients has evolved significantly in recent years, particularly with the development of the current-generation PSMA targeted products. The approved PSMA PET products have high specificity, however, due to their low sensitivity, especially in patients with low PSA, a considerable proportion of patients have no detectable disease on the scans while their PSA continues to rise, indicating recurrence of their cancer. With no clear visualisation of where the cancer is located, planning effective treatments is challenging. Early intervention is essential in order to achieve cure in BCR, and the need for more sensitive diagnostics remains. This unmet need is what led us to design the Co-PSMA study.

"The data generated thus far on 64Cu-SAR-bisPSMA in the PROPELLER and COBRA trials are very encouraging. The high lesion uptake and retention of the product over time provides better visualisation on same-day imaging compared to SOC imaging. Furthermore, the delayed imaging, enabled by the longer half-life of copper-64 compared to gallium-68 and fluorine-18, increases image contrast, helping to identify smaller lesions and allowing more flexible scheduling of patients. If the Co-PSMA trial confirms that 64Cu-SAR-bisPSMA can detect more lesions than 68Ga-PSMA-11 in this patient group with such low PSA, this may improve image-guided therapy, potentially avoiding complications and improving outcomes. We look forward to reporting the trial results in the coming months."

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

About Prostate Cancer
Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide6. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease.

On July 17, 2025 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, reported that it will host a virtual R&D Day at 1:30 PM PT on Thursday, July 24, 2025 (Press release, Janux Therapeutics, JUL 17, 2025, View Source [SID1234654435]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux’s expertise and platform technologies to potentially address significant unmet medical needs.

Event Information

To join the webcast, please visit this link, or the Events & Presentations page of the Investors section on the Company’s website at View Source A replay of the webcast will be archived and available following the event.

Participant Dial-In Numbers:
USA / International +1 (646) 307-1963
USA – Toll-Free (800) 715-9871
Conference ID 9235403

Janux’s TRACTr and TRACIr Pipeline

Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with metastatic castration-resistant prostate cancer. Janux’s second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. We are also generating a number of additional TRACTr and TRACIr programs for potential future development, some of which are at development candidate stage or later. We are currently assessing priorities in our preclinical pipeline.

On July 17, 2025 Abbott (NYSE: ABT) reported financial results for the second quarter ended June 30, 2025 (Press release, Abbott, JUL 17, 2025, View Source [SID1234654420]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1.
Second-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.26, which excludes specified items and reflects double-digit growth compared to the prior year.
First-half sales increased 5.7 percent on a reported basis, 6.9 percent on an organic basis, or 7.9 percent when excluding COVID-19 testing-related sales2.
Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.
Abbott projects full-year 2025 adjusted diluted EPS of $5.10 to $5.20, which reflects double-digit growth at the midpoint.
In April, Abbott completed enrollment ahead of schedule in its FlexPulse U.S. IDE trial, which is designed to evaluate the TactiFlex Duo Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib).
In April, Abbott announced late-breaking data from the AVEIR Conduction System Pacing (CSP) clinical feasibility study. This study was the world’s first assessment of a leadless pacemaker delivering conduction pacing, which produces pacing that closely mimics the heart’s natural electrical rhythm and represents a new treatment option for people with irregular heart rhythms.
In May, Abbott announced U.S. Food and Drug Administration (FDA) approval of the company’s Tendyne transcatheter mitral valve replacement (TMVR) system, a first-of-its-kind device to help treat people with mitral valve disease.
Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028.
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline," said Robert B. Ford, chairman and chief executive officer, Abbott. "We see this momentum carrying into 2026."

SECOND-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes thatmeasuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to bestunderstand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Second Quarter 2025 Results (2Q25)

Sales 2Q25 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

4,276

957

811

—

2,503

International

6,866

1,255

1,362

1,383

2,866

Total reported

11,142

2,212

2,173

1,383

5,369

% Change vs. 2Q24

U.S.

8.7

2.6

(0.1)

n/a

14.6

International

6.6

3.1

(1.5)

6.9

12.4

Total reported

7.4

2.9

(1.0)

6.9

13.4

Impact of foreign exchange

0.5

(0.5)

0.4

(0.8)

1.2

Organic

6.9

3.4

(1.4)

7.7

12.2

Impact of COVID-19 testing sales 1

(0.6)

—

(2.2)

—

—

Organic (excluding COVID-19 tests)

7.5

3.4

0.8

7.7

12.2

Organic

U.S.

8.7

2.6

(0.1)

n/a

14.6

International

5.8

4.0

(2.2)

7.7

10.1

First Half 2025 Results (1H25)

Sales 1H25 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

8,444

1,912

1,682

—

4,842

International

13,056

2,446

2,545

2,643

5,422

Total reported

21,500

4,358

4,227

2,643

10,264

% Change vs. 1H24

U.S.

8.5

5.6

(3.5)

n/a

14.8

International

3.9

1.6

(4.5)

4.9

9.1

Total reported

5.7

3.3

(4.1)

4.9

11.7

Impact of foreign exchange

(1.1)

(1.5)

(0.9)

(2.9)

(0.7)

Impact of business exit*

(0.1)

(0.3)

—

—

—

Organic

6.9

5.1

(3.2)

7.8

12.4

Impact of COVID-19 testing sales 2

(1.0)

—

(3.9)

—

—

Organic (excluding COVID-19 tests)

7.9

5.1

0.7

7.8

12.4

Organic

U.S.

8.7

6.4

(3.5)

n/a

14.8

International

5.8

4.1

(3.0)

7.8

10.3

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.

*Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024.

Nutrition

Second Quarter 2025 Results (2Q25)

Sales 2Q25 ($ in millions)

Total

Pediatric

Adult

U.S.

957

587

370

International

1,255

467

788

Total reported

2,212

1,054

1,158

% Change vs. 2Q24

U.S.

2.6

4.2

0.2

International

3.1

(5.7)

9.2

Total reported

2.9

(0.4)

6.1

Impact of foreign exchange

(0.5)

(0.6)

(0.5)

Organic

3.4

0.2

6.6

U.S.

2.6

4.2

0.2

International

4.0

(4.5)

9.8

Worldwide Nutrition sales increased 2.9 percent on a reported basis and 3.4 percent on an organic basis in the second quarter.

Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1 percent on a reported basis and 6.6 percent on an organic basis, led by strong growth of Ensure, Abbott’s market-leading complete and balanced nutrition brand, and Glucerna, Abbott’s market-leading brand of products designed to meet the nutritional requirements for people with diabetes.

First Half 2025 Results (1H25)

Sales 1H25 ($ in millions)

Total

Pediatric

Adult

U.S.

1,912

1,175

737

International

2,446

920

1,526

Total reported

4,358

2,095

2,263

% Change vs. 1H24

U.S.

5.6

9.0

0.6

International

1.6

(7.0)

7.7

Total reported

3.3

1.3

5.3

Impact of foreign exchange

(1.5)

(1.2)

(1.6)

Impact of business exit*

(0.3)

—

(0.7)

Organic

5.1

2.5

7.6

U.S.

6.4

9.0

2.4

International

4.1

(4.6)

10.2

*Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024.

Diagnostics

Second Quarter 2025 Results (2Q25)

Sales 2Q25 ($ in millions)

Total

Core Laboratory

Molecular

Point of Care

Rapid
Diagnostics

U.S.

811

351

35

104

321

International

1,362

1,007

88

44

223

Total reported

2,173

1,358

123

148

544

% Change vs. 2Q24

U.S.

(0.1)

7.3

5.5

(2.0)

(7.1)

International

(1.5)

0.5

(5.6)

(11.9)

(6.1)

Total reported

(1.0)

2.2

(2.7)

(5.1)

(6.7)

Impact of foreign exchange

0.4

0.6

0.7

0.1

0.1

Organic

(1.4)

1.6

(3.4)

(5.2)

(6.8)

U.S.

(0.1)

7.3

5.5

(2.0)

(7.1)

International

(2.2)

(0.3)

(6.5)

(12.1)

(6.3)

Global Diagnostics sales decreased 1.0 percent on a reported basis, decreased 1.4 percent on an organic basis, and increased 0.8 percent when excluding COVID-19 testing-related sales1.

Diagnostics sales growth was impacted by the year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China.

COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million in the second quarter of the prior year.

Global Core Laboratory Diagnostics sales increased 2.2 percent on a reported basis and increased 1.6 percent on an organic basis. Growth in the quarter was impacted by volume-based procurement programs in China.

First Half 2025 Results (1H25)

Sales 1H25 ($ in millions)

Total

Core Laboratory

Molecular

Point of Care

Rapid
Diagnostics

U.S.

1,682

683

75

204

720

International

2,545

1,852

170

86

437

Total reported

4,227

2,535

245

290

1,157

% Change vs. 1H24

U.S.

(3.5)

7.2

—

(0.3)

(12.8)

International

(4.5)

(2.4)

(6.1)

(4.5)

(12.3)

Total reported

(4.1)

0.1

(4.4)

(1.6)

(12.6)

Impact of foreign exchange

(0.9)

(1.2)

(1.0)

(0.4)

(0.6)

Organic

(3.2)

1.3

(3.4)

(1.2)

(12.0)

U.S.

(3.5)

7.2

—

(0.3)

(12.8)

International

(3.0)

(0.7)

(4.9)

(3.3)

(10.7)

Established Pharmaceuticals

Second Quarter 2025 Results (2Q25)

Sales 2Q25 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

1,383

1,059

324

Total reported

1,383

1,059

324

% Change vs. 2Q24

U.S.

n/a

n/a

n/a

International

6.9

7.3

5.9

Total reported

6.9

7.3

5.9

Impact of foreign exchange

(0.8)

(1.4)

1.4

Organic

7.7

8.7

4.5

U.S.

n/a

n/a

n/a

International

7.7

8.7

4.5

Established Pharmaceuticals sales increased 6.9 percent on a reported basis and 7.7 percent on an organic basis in the second quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 7.3 percent on a reported basis and 8.7 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East.

First Half 2025 Results (1H25)

Sales 1H25 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

2,643

2,024

619

Total reported

2,643

2,024

619

% Change vs. 1H24

U.S.

n/a

n/a

n/a

International

4.9

5.7

2.4

Total reported

4.9

5.7

2.4

Impact of foreign exchange

(2.9)

(3.3)

(1.4)

Organic

7.8

9.0

3.8

U.S.

n/a

n/a

n/a

International

7.8

9.0

3.8

Medical Devices

Second Quarter 2025 Results (2Q25)

Sales 2Q25 ($ in millions)

Total

Rhythm
Management

Electro-

physiology

Heart
Failure

Vascular

Structural
Heart

Neuro-
modulation

Diabetes
Care

U.S.

2,503

340

322

282

283

289

193

794

International

2,866

333

378

86

474

347

61

1,187

Total reported

5,369

673

700

368

757

636

254

1,981

% Change vs. 2Q24

U.S.

14.6

16.5

12.2

15.8

3.0

12.2

0.4

24.5

International

12.4

5.7

10.9

11.2

5.4

13.7

20.4

17.5

Total reported

13.4

10.9

11.5

14.7

4.5

13.0

4.6

20.2

Impact of foreign exchange

1.2

1.1

1.2

0.7

1.0

1.3

0.3

1.7

Organic

12.2

9.8

10.3

14.0

3.5

11.7

4.3

18.5

U.S.

14.6

16.5

12.2

15.8

3.0

12.2

0.4

24.5

International

10.1

3.6

8.8

8.4

3.8

11.4

18.7

14.7

Worldwide Medical Devices sales increased 13.4 percent on a reported basis and 12.2 percent on an organic basis in the second quarter.

Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart and Electrophysiology.

Several products contributed to the strong performance, including FreeStyle Libre, Navitor, TriClip and AVEIR.

In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4 percent on a reported basis and 19.6 percent on an organic basis.

First Half 2025 Results (1H25)

Sales 1H25 ($ in millions)

Total

Rhythm
Management

Electro-

physiology

Heart
Failure

Vascular

Structural
Heart

Neuro-
modulation

Diabetes
Care

U.S.

4,842

644

621

544

551

571

369

1,542

International

5,422

614

708

163

916

642

113

2,266

Total reported

10,264

1,258

1,329

707

1,467

1,213

482

3,808

% Change vs. 1H24

U.S.

14.8

14.4

11.7

13.2

4.2

16.3

(1.1)

25.7

International

9.1

1.2

7.6

12.6

3.5

9.3

18.5

13.8

Total reported

11.7

7.6

9.5

13.1

3.8

12.5

2.9

18.4

Impact of foreign exchange

(0.7)

(0.4)

(0.6)

(0.2)

(0.7)

(0.7)

(0.4)

(0.7)

Organic

12.4

8.0

10.1

13.3

4.5

13.2

3.3

19.1

U.S.

14.8

14.4

11.7

13.2

4.2

16.3

(1.1)

25.7

International

10.3

2.0

8.8

13.4

4.8

10.5

20.5

15.0

ABBOTT’S FINANCIAL GUIDANCE
Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.

Abbott projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales.

Abbott projects full-year 2025 adjusted diluted earnings per share of $5.10 to $5.20 and third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott’s results in accordance with GAAP.

ABBOTT DECLARES 406th CONSECUTIVE QUARTERLY DIVIDEND
On June 13, 2025, the board of directors of Abbott declared the company’s quarterly dividend of $0.59 per share. Abbott’s cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025.

Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

On July 17, 2025 MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, reported that the first patient has been dosed in its Phase 1 clinical trial to assess the safety and tolerability of MOMA-341, a potent and selective Werner helicase inhibitor with a novel chemical scaffold (Press release, MOMA Therapeutics, JUL 17, 2025, View Source [SID1234654436]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MOMA-341 is being developed as a monotherapy and in combination with chemotherapy or immunotherapy for the treatment of advanced or metastatic solid tumors that exhibit high microsatellite instability (MSI-H) and/or DNA mismatch repair deficiency (dMMR), including colorectal, gastric and endometrial cancers. The fact that Werner helicase is required for survival of MSI-H/dMMR tumor cells makes it a promising emerging drug target. MOMA anticipates an initial readout of monotherapy data in mid-2026.

"We are proud to enter the clinic for the second time in less than a year, with initial readouts for both MOMA-341 and MOMA-313, our novel Polθ helicase inhibitor, expected in early-to- mid 2026," said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA. "Given that MOMA-341’s novel chemical scaffold confers excellent target coverage, we are eager to evaluate its best-in-class potential for patients through this Phase 1 study."

About the MOMA-341 Phase 1 Trial

The Phase 1 clinical trial is a global multi-center, open-label dose escalation and dose optimization study (NCT06974110) designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity of MOMA-341 as an orally administered single agent or combination therapy with either the chemotherapy agent irinotecan or immunotherapy. Adult participants must have unresectable advanced or metastatic microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.

About the KNOMATIC platform

MOMA-341 and MOMA-313, were discovered and developed through the application of MOMA’s KNOMATIC platform. The KNOMATIC platform integrates deep structural insights, advanced hit-finding technologies and computation-enabled lead optimization to accelerate discovery of novel therapeutics targeting families of highly dynamic proteins, such as ATPases and GTPases.